drugset / Trial / NCT04100330
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in subjects with relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2020-01-31
- Primary completion
- 2020-03-27
- Completion
- 2020-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 2 g | Intravenous |
| Subject | Ficlatuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |